Please provide your email address to receive an email when new articles are posted on . Benralizumab induces depletion of eosinophils and mepolizumab reduces activation. The study followed patients ...

Severe eosinophilic asthma (SEA) is a debilitating respiratory condition characterized by persistent airway inflammation and high eosinophil levels, resulting in frequent exacerbations and significant ...

Please provide your email address to receive an email when new articles are posted on . Women with asthma outnumber men by about 3 to 1. Asthma encounters accounted for 4% of ED and inpatient visits.

What Is Exdensur, and Why Does It Matter? Exdensur (depemokimab) is a new type of ultra long-acting biologic medicine approved by the FDA as an add-on maintenance treatment for severe eosinophilic ...

Specific sputum markers, including higher sputum eosinophils, macrophages, and lymphocyte counts, were associated with remission after interleukin-5 (IL-5)–targeted therapy for patients with severe ...

China: Researchers have found in a new meta-analysis that mepolizumab is an effective and safe treatment for severe ...

The FDA approved depemokimab (Exdensur) as the first ultra-long-acting biologic with twice-yearly dosing approved for patients with severe asthma with an eosinophilic phenotype, GSK announced. The ...

Etokimab (I-Mab Biopharma), which is optimized for common IL-33 gene polymorphisms, has completed patient recruitment in its ...

The U.S. Food and Drug Administration (FDA) has granted approval to GSK’s Exdensur, a new biologic medication for people with severe eosinophilic asthma aged 12 and older (1). This decision marks a ...